Metsera Stock Rises As Company Advances Obesity Pipeline With Encouraging Weight Loss Data
1. MTSR's MET-233i shows up to 8.4% weight loss at Day 36. 2. 19-day half-life suggests potential for once-monthly dosing. 3. No severe adverse events reported in clinical trials. 4. Ongoing trials for MET-233i and MET-097i present promising future data. 5. MTSR stock increased by 13.24% following positive trial results.